Marshall Wace, LLP Chroma Dex Corp. Transaction History

Marshall Wace, LLP

$81.7 Billion
Q2 2025

A detailed history of Marshall Wace, LLP transactions in Chroma Dex Corp. stock. As of the latest transaction made, Marshall Wace, LLP holds 162,133 shares of CDXC stock, worth $995,496. This represents 0.0% of its overall portfolio holdings.

Number of Shares

162,133

Previous 298,977 45.77%

Holding current value

$995,496

Previous $2.06 Million 51.75%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 13, 2025	SELL	$5.42 - $7.08 $741,694 - $968,855	-136,844 Reduced 45.77%	162,133 $995,000
Q1 2025 May 15, 2025	BUY	$5.26 - $8.55 $1.57 Million - $2.56 Million	298,977 New	298,977 $2.06 Million
Q2 2024 Aug 14, 2024	BUY	$2.44 - $4.32 $50,207 - $88,892	20,577 New	20,577 $56,000
Q1 2023 May 15, 2023	SELL	$1.48 - $2.19 $70,288 - $104,007	-47,492 Reduced 57.85%	34,600 $52,000
Q3 2022 Nov 14, 2022	BUY	$1.19 - $2.06 $38,842 - $67,240	32,641 Added 66.01%	82,092 $101,000
Q2 2022 Aug 15, 2022	SELL	$1.59 - $2.7 $45,505 - $77,274	-28,620 Reduced 36.66%	49,451 $83,000
Q1 2022 May 16, 2022	BUY	$2.02 - $3.92 $157,703 - $306,038	78,071 New	78,071 $193,000
Q4 2021 Feb 14, 2022	SELL	$3.74 - $6.7 $332,366 - $595,415	-88,868 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$6.05 - $10.41 $61,347 - $105,557	10,140 Added 12.88%	88,868 $557,000
Q2 2021 Aug 13, 2021	SELL	$6.66 - $10.92 $1.23 Million - $2.01 Million	-184,114 Reduced 70.05%	78,728 $776,000
Q1 2021 May 17, 2021	BUY	$4.59 - $18.74 $1.21 Million - $4.93 Million	262,842 New	262,842 $2.46 Million

Others Institutions Holding CDXC

# of Institutions

167

Shares Held

27.9M

Call Options Held

152K

Put Options Held

178K

View Full List

About ChromaDex Corp.

Ticker CDXC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,350,896
Market Cap $420M
Description
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingre...

More about CDXC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Account

Marshall Wace, LLP Chroma Dex Corp. Transaction History